In the present study, plasma LeXis was significantly upregulated in NASH and was also found to be a specific biomarker for NASH diagnosis in patients with NAFLD, regardless of other clinical factors such as hypertension and diabetes, or the levels of aminotransferase, creatinine, and platelets. The gene discussed is CT70; the disease is metabolic dysfunction-associated steatohepatitis.